MLK3 (phospho-T277/S281) polyclonal Antibody | BS64014

MLK3 (phospho-T277/S281) polyclonal Antibody | BS64014 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB

Application Range: WB: 1:500~1:1000

Background: As a result of the binding of growth factors to their membrane receptors, cytoplasmic proteins containing Src homology 2 (SH2) domains associate with specific phosphotyrosine residues within the activated receptors and function as signaling intermediates. The action of such SH2 domain proteins frequently involves the activation of a second group of signaling intermediates characterized by SH3 domains. These latter proteins function through binding proline-rich sequences in target proteins. A novel human non-receptor protein kinase, designated either MLK3 or PTK1, is 847 amino acids in length and contains an SH3 domain in the absence of an SH2 domain. In addition, MLK3 is characterized by a leucine zipper basic region (a motif commonly associated with transcription factors) and has a long carboxy-terminal tail which exhibits proline-rich motifs similar to known SH3 binding sites. MLK3 is expressed widely and is related to the previously described MLK1 and MLK2 kinases.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: p-MLK3 (T277/S281) polyclonal Antibody detects endogenous levels of human MLK3 when phosphorylated at Thr602 and Ser281.

Molecular Weight: ~ 93, 100 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Mitogen-activated protein kinase kinase kinase 11; Mixed lineage kinase 3; Src-homology 3 domain-containing proline-rich kinase; MAP3K11; MLK3; PTK1; SPRK

Immunogen: Synthetic phosphopeptide derived from human MLK3 around the phosphorylation site of Threonine 277 and Serine281.

Conjugate: Unconjugated

Modification: Phosphorylation

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: